Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Research from Worldpanel by Numerator found that the share of British households containing a GLP-1 user rose from 2.3% in 2024 to 6.3% in 2026
Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management), tirzepatide represents a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists
It's a complete medical program
Share everything
Viking Therapeutics - VK2735 (oral, dual GLP1/GIP agonist) Viking Therapeutics is actively developing VK2735, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, with both subcutaneous and oral formulations in its pipeline
US$ 21.26
US$ 20.97
US$ 23.83
US$ 22.58
US$ 21.76
